Stefanelli Victoria, Lombardi Jared, Ferrer Joselito, Gardocki-Sandor Maryellen
Allergan Aesthetics, an AbbVie Company, Branchburg, New Jersey, USA.
Tissue Eng Part A. 2025 May;31(9-10):419-432. doi: 10.1089/ten.TEA.2024.0059. Epub 2024 Aug 19.
Four human acellular dermal matrices (hADMs) were characterized in a nonhuman primate abdominal wall repair model by evaluating host immune response, vascularization, and incorporation into host tissues. AlloDerm™ (electron beam-sterilized hADM [e-hADM]), AlloMax™ (gamma beam-sterilized hADM, freeze-dried [g-hADM-FD]), DermaMatrix™ (hADM, freeze-dried [hADM-FD]), and FlexHD™ (ethanol-treated hADM [EtOH-hADM]) were each implanted in an abdominal wall-bridging defect in nonhuman primates ( = 3 animals/time point, = 36 animals). Immunohistochemical and histological assessments were conducted on biopsies from each hADM at 1-, 3-, and 6-months postimplantation to assess vascularization (hematoxylin and eosin [H&E], CD31, alpha smooth muscle actin [αSMA], collagen IV), inflammatory/immune response (H&E, CD3, CD20, CD68), and collagen turnover (H&E, matrix metalloproteinase-9 [MMP-9]). MMP-9 immunolabeling was similar among different hADMs at 1 month; however, hADM-FD and EtOH-hADM showed higher total mean MMP-9-immunopositive areas at approximately 16% compared with <1% for e-hADM and g-hADM at 6 months postimplantation. Cells that stained positively for CD68, CD3, and CD20 were generally higher for hADM-FD and EtOH-hADM compared with other hADMs. The mean CD31-immunopositive area, CD31 vessel density, CD31 vessel diameter, and collagen IV-immunopositive area increased over time. Among all the hADM types, e-hADM had the highest mean (±standard deviation [SD]) CD31-immunopositive area at 1.54% ± 1.01%, vessel density at 7.86 × 10 ± 3.96 × 10 vessels/µm, and collagen IV-immunopositive area at 2.55% ± 0.73% 1-month postimplantation. The pattern of αSMA immunolabeling varied among the hADMs. Histology showed that overall inflammation was mild at 1 month. Overall fibroblast repopulation and collagen remodeling increased over time from 1 to 6 months postimplantation. Fibroblast infiltration was minimal to mild at 1 month, with e-hADM showing the highest mean (±SD) score at 2.00 ± 0.00 compared with other hADMs. Only hADM-FD was not completely replaced by neotissue formation at 6 months postimplantation. All hADMs promoted vascularization, cell infiltration, and incorporation into host tissue, which were associated with acute inflammation and immune responses, within a 6-month period. A trend toward relatively enhanced early vascularization in e-hADM compared with other hADMs was observed. Immunogenic responses among the hADMs in the present study showed a slight distinction toward more quiescent terminally sterilized hADMs (e-hADM, g-hADM-FD) versus aseptically processed hADMs (EtOH-hADM, hADM-FD).
通过评估宿主免疫反应、血管生成以及与宿主组织的整合情况,在非人类灵长类动物腹壁修复模型中对四种人脱细胞真皮基质(hADM)进行了特性分析。将AlloDerm™(电子束灭菌的hADM [e-hADM])、AlloMax™(γ射线灭菌的冻干hADM [g-hADM-FD])、DermaMatrix™(冻干hADM [hADM-FD])和FlexHD™(乙醇处理的hADM [EtOH-hADM])分别植入非人类灵长类动物的腹壁桥接缺损处(每个时间点n = 3只动物,共n = 36只动物)。在植入后1个月、3个月和6个月时,对取自每种hADM的活检组织进行免疫组织化学和组织学评估,以评估血管生成(苏木精和伊红染色 [H&E]、CD31、α平滑肌肌动蛋白 [αSMA]、胶原蛋白IV)、炎症/免疫反应(H&E、CD3、CD20、CD68)以及胶原蛋白周转(H&E、基质金属蛋白酶-9 [MMP-9])。在1个月时,不同hADM之间的MMP-9免疫标记相似;然而,在植入后6个月时,hADM-FD和EtOH-hADM的总平均MMP-9免疫阳性面积较高,约为16%,而e-hADM和g-hADM的该面积小于1%。与其他hADM相比,hADM-FD和EtOH-hADM中CD68、CD3和CD20染色阳性的细胞通常更多。平均CD31免疫阳性面积、CD31血管密度、CD31血管直径和胶原蛋白IV免疫阳性面积随时间增加。在所有hADM类型中,e-hADM在植入后1个月时的平均(±标准差 [SD])CD31免疫阳性面积最高,为1.54% ± 1.01%,血管密度为7.86×10 ± 3.96×10个血管/μm,胶原蛋白IV免疫阳性面积为2.55% ± 0.73%。hADM之间αSMA免疫标记的模式各不相同。组织学显示,1个月时总体炎症较轻。从植入后1个月到6个月,总体成纤维细胞再填充和胶原蛋白重塑随时间增加。1个月时成纤维细胞浸润极少至轻度,与其他hADM相比,e-hADM的平均(±SD)评分最高,为2.00 ± 0.00。在植入后6个月时,只有hADM-FD没有被新组织形成完全替代。在6个月的时间内,所有hADM均促进了血管生成、细胞浸润以及与宿主组织的整合,这与急性炎症和免疫反应相关。观察到与其他hADM相比,e-hADM早期血管生成有相对增强的趋势。本研究中hADM之间的免疫原性反应显示,与无菌处理的hADM(EtOH-hADM、hADM-FD)相比,终末灭菌的hADM(e-hADM、g-hADM-FD)相对更不活跃,二者略有区别。